Synergistic antiproliferative and proapoptotic activity was achieved when Lillys PKC inhibitor Enzastaurin was added after prior gemcitabine and pemetrexed in vitro in human NSCLC cell lines. This effect was not observed when Enzastaurin was added first.
Filed under: kinase | Tagged: Enzastaurin, Lilly, PKC, pkcbeta, Preclinical, protein kinase c, Research | Comments Off
